Trials / Withdrawn
WithdrawnNCT02326779
Low-dose Aspirin Therapy for Esophageal Cancer
Low-dose Aspirin Therapy for Stage II-III Esophageal Cancer- A Multi-Center, Open Label, Randomized Controlled Phase III Trial
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the survival benefit of low-dose aspirin use for stage II-III esophageal cancer patients.
Detailed description
The investigators aimed to evaluate the hypothesis that low-dose aspirin can improve survival in stage II-III esophageal cancer patients, and to evaluate whether this effect is influenced by PIK3CA, KRAS, BRAF mutation and COX-2 expression. Eligible participants will be randomized to either aspirin treatment arm (100 mg aspirin OD for 3 years), or non-aspirin user arm in 1:1 ratio. After randomization, participants will receive 3 monthly assessments during treatment and follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acetylsalicylic acid | Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2018-10-01
- Completion
- 2018-12-01
- First posted
- 2014-12-29
- Last updated
- 2021-04-27
Source: ClinicalTrials.gov record NCT02326779. Inclusion in this directory is not an endorsement.